Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
<a class="twitter-timeline" data-width="500" data-height="500" data-theme="light" href="https://twitter.com/
<a href="https://twitter.com/cancerGRACE?ref_src=twsrc%5Etfw" class="twitter-follow-button" data-show-count="false">Follow @cancerGRACE</a><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<iframe loading="lazy" src="https://cancerGRACE.org" style="border:0px #ffffff none;" name="cancerGRACE" scrolling="no" frameborder="1" marginheight="0px" marginwidth="0px" height="700px" width="700px" allowfullscreen></iframe>
<iframe loading="lazy" src="https://twitter.com/CancerGRACE" style="border:0px #ffffff none;" name="@cancerGRACE" scrolling="no" frameborder="1" marginheight="0px" marginwidth="0px" height="700px" width="700px" allowfullscreen></iframe>
https://twitter.com/CancerGRACE
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…